News | July 03, 2023
Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
The VITA-FAST tokens have been met with overwhelming interest
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions
Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing
New reforestation projects in Brazil, India, Vietnam, Ghana and Rwanda in addition to existing projects including in Australia and Indonesia
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Subscribe To Our Newsletter & Stay Updated
